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Background: Aim of the study was to compare the effect of neuroleptic sedation with acepromazine and
neuroleptanalgesia with acepromazine and buprenorphine on thermal thresholds (TT) obtained at the nostrils and
at the withers. The study was carried out as a randomized, blinded, controlled trial with cross-over design. Thermal
thresholds were determined by incremental contact heat applied to the skin above the nostril (N) or the withers
(W). Eleven horses were treated with saline (S), acepromazine (0.05 mg/kg) (ACE) or acepromazine and
buprenorphine (0.0075 mg/kg) (AB) intravenously (IV). Single stimulations were performed 15 minutes prior and 15,
45, 75, 105, 165, 225, 285, 405 and 525 minutes after treatment. Sedation score, gastrointestinal auscultation score
and occurrence of skin lesions were recorded. Data were analysed with analysis of variance for repeated
measurements.
Results: There were no significant differences in TT between N and W with all treatments. The TT remained
constant after S and there was no difference in TT between S and ACE. After AB there was a significant increase
above baseline in TT until 405 minutes after treatment. Restlessness occurred 30–90 minutes after AB in 7 horses.
All horses had reduced to absent borborygmi after AB administration for 165 to 495 minutes.
Conclusion: Thermal stimulation at both described body areas gives comparable results in the assessment of
cutaneous anti-nociception in horses. There is no differential influence of neuroleptic sedation or
neuroleptanalgesia on TTs obtained at N or W. Buprenorphine combined with acepromazine has a long lasting
anti-nociceptive effect associated with the typical opioid induced side effects in horses.
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Thermal stimulation is a natural modality to induce
nociception. In addition, it is able to stimulate C-fibre
nociceptors and is therefore suitable to detect opioid in-
duced antinociception [1,2]. In horses, radiant heat
stimulating the lateral aspect of the fetlock, the coronary
band and the withers was used to determine the latency
of the hoof withdrawal reflex (HWR) or skin twitching
reflex (STR) after fentanyl [3], local anaesthetics [4] or
buprenorphine [5]. Contact heat thermal threshold test-
ing by ramped heating has been used for the detection
of the analgesic efficacy of lidocaine [6], fentanyl and* Correspondence: c.poller@gmx.ne
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reproduction in any medium, provided the orbutorphanol [7,8] and buprenorphine [9] in horses by
performing thermal stimulation at the withers.
However, the type of nocifensive response and its
detection varies between body regions and might there-
fore influence the determination of thermal thresholds.
Transmission of a noxious stimulus at the body travels
through the dorsal horn of the spinal cord and ascends
to the brain via the spinothalamic tract [10]. Assessment
of the skin twitch in response to nociceptive stimulation
at the withers involves direct reflex pathways (cutaneous
trunci reflex). In contrast, sensory innervation of the
forehead is carried by the trigeminal nerve and the tri-
geminal ganglion entering the brainstem at the level of
the pons [10]. Nocifensive reflexes in response to painful
stimulation of the tooth root (“jaw opening reflex”) or
the supraorbital nerve (trigeminocervical reflex) withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Mean (± SD) thermal threshold temperature (°C) in 11
horses at the withers or nostrils. Mean (± SD) thermal threshold
temperature (°C) in 11 horses at the withers or nostrils treated with
saline, acepromazine or acepromazine + buprenorphine 0: baseline
measurement; Ti: time point of injection (15 min); *: significant
(p < 0.05) difference in thermal threshold compared to baseline A:
thermal threshold temperatures at the nostril B: thermal threshold
temperatures at the withers.
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scribed in different species [11-13]. However, coordi-
nated behaviour like head shaking or rubbing the face
against an object can be considered as result of con-
scious perception. Nociceptive stimulation at the head
or the body might result in differences in thermal
thresholds, depending on recognition and definition of
end points. In addition, drugs affecting alertness might
have differential influences on reflex responses and con-
scious reactions.
Therefore, the aim of the study was to compare the ef-
fect of neuroleptic sedation with acepromazine and
neuroleptanalgesia with acepromazine and buprenorphine
on TTs obtained at the nostrils and at the withers. The
hypothesis was that neuroleptic sedation and neurolept-
analgesia would inhibit conscious reactions to a greater
extent than reflex responses.
Results
Skin temperature
There was no significant change in skin temperature at
N over the course of the experiment in group S or ACE,
but in group AB there was a statistically significant in-
crease in skin temperature over the first measurements
(Table 1). Skin temperatures at the withers increased sig-
nificantly in group S and AB for the first measurements
and decreased significantly in group ACE 165 minutes
after injection for the next four hours (Table 1).
Thermal threshold
Thermal threshold temperatures at the nostril did not
change over the observation period in group S and
group ACE (Figure 1A). In group AB, TTs were signifi-
cantly increased from 15 minutes until 405 minutesTable 1 Mean (± SD) skin temperatures in 11 horses at the withers or nostrils
Medication Saline solution Acepromazine (0.05 mg/kg) Acepromazine (0.05 mg/kg)/
Buprenorphine (0.0075 mg/kg)
Location/ Time (min) Nostril (°C) Withers (°C) Nostril (°C) Withers (°C) Nostril (°C) Withers (°C)
Baseline 31.8 ± 2.2a 31.2 ± 2.5a 31.1 ± 2.6a 32.1 ± 1.7a 31.7 ± 1.6a 30.8 ± 2.4a
15 32.8 ± 1.1a 32.8 ± 1.3b 31.9 ± 1.5a 32.9 ± 1.4a 32.9 ± 1.6b 33.6 ± 2.1b
45 32.7 ± 0.5a 32.9 ± 1.2b 32.9 ± 0.9b 32.8 ± 1.6a 33.2 ± 1.2b 33.1 ± 1.2b
75 32.6 ± 1.0a 32.7 ± 1.0b 32.3 ± 1.6a 32.4 ± 1.9a 33.2 ± 1.2b 33.1 ± 1.0b
105 32.9 ± 0.7a 33.2 ± 1.0b 31.8 ± 1.7a 32.1 ± 1.5a 32.5 ± 1.2a 32.8 ± 1.1b
165 32.1 ± 0.9a 31.1 ± 1.4a 31.1 ± 1.4a 30.1 ± 2.1b 32.4 ± 1.7a 31.1 ± 2.6a
225 31.9 ± 1.0a 31.1 ± 1.1a 30.9 ± 1.7a 29.7 ± 1.8b 32.2 ± 1.3a 31.4 ± 2.1a
285 31.4 ± 1.0a 31.7 ± 1.3a 31.4 ± 1.2a 30.0 ± 2.0b 32.5 ± 1.1a 31.9 ± 2.1a
405 31.7 ± 0.9a 31.1 ± 1.5a 31.6 ± 1.5a 30.3 ± 1.8b 32.4 ± 0.9a 31.4 ± 2.0a
525 31.8 ± 1.0a 31.5 ± 1.6a 31.6 ± 1.8a 31.5 ± 2.1a 32.5 ± 1.8a 32.2 ± 2.1b
Mean (± SD) skin temperatures in 11 horses at the withers or nostrils treated with saline, acepromazine or acepromazine + buprenorphine intravenously. Fifteen
minutes before drug administration baseline measurement was performed and the first measurement was started 15 minutes after drug injection.
a, b = values with different superscripts differ significantly within each treatment group (p < 0.05).
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(Figure 1A) and compared to TTs in group S and group
ACE. At W, there was also no change in TTs after treat-
ment in group S and group ACE (Figure 1B). Similar to
stimulation at N TTs increased above baseline in group
AB from 45 to 405 minutes after treatment (Figure 1B).
During the same period TTs in group AB were signifi-
cantly increased compared to group S and group ACE.
Thermal thresholds were not different between N and
W. Analysis based on standardized thermal excursion
(TE %) did not change the results (Figure 2A,B).
Reaction to stimulation, sedation and side effects
The most frequent reaction to thermal stimulation at N
was head shaking (54.2%) followed by rubbing the face
(44.4%). Stimulation at W was mostly answered with
skin twitching (86.7%) rarely with shaking the whole
body (12.8%) or turning the head towards the stimulus
(0.5%).Figure 2 TE (%) in 11 horses at the withers or nostrils. TE (%) in
11 horses at the withers or nostrils treated with saline, acepromazine
or acepromazine + buprenorphine TE % = 100 × ([TT ‐ T0]/[Tc ‐ T0]).
TT is the thermal threshold temperature, T0 is the skin temperature
and Tc is the thermal cut-out temperature. 0: baseline measurement;
Ti: time point of injection (15 min); *: significant (p < 0.05) difference
in thermal threshold compared to baseline A: TE (%) at the nostril B:
TE (%) at the withers.All horses became mildly to moderately sedated (score:
4 [1,9]) 15 minutes after ACE lasting for 60 to 150 mi-
nutes (99 ± 28 min). In group AB, a median sedation
score of 3 [0,9] was reached and sedation lasted 30 to
210 minutes (85 ± 64 min). In this group 1 horse did
not become sedated and another horse was deeply se-
dated (score: 8).
Gastrointestinal sounds were reduced or absent from
15 to 75 minutes after AB administration and lasted for
180 to 510 minutes (297 ± 124 min). The horse not
showing signs of sedation in group AB developed signs
of colic one hour after the experiment was completed.
An impaction of the large colon was diagnosed and
treated medically without further complications. In
group AB, excitatory phenomena like restlessness and
box walking were observed in 10 of 11 horses starting
with waning sedative effects of acepromazine (Additional
file 1). After treatment with AB restlessness persisted for
60 to 480 minutes (297 ± 160 min), in 7 horses restless-
ness started 15 to 75 minutes after injection, in 3 horses
165 to 225 minutes after drug administration. Increased
salivation or tear production was observed in four horses
15 minutes after injection of AB for up to 60 minutes.Skin lesions
Mild swelling without pain on palpation occurred at the
nostrils in group AB occasionally when the thermode
was heated up to cut-out temperature. There were no
skin lesions after administration of S or ACE.Buprenorphine pharmacokinetics
The semilogarithmic serum concentration vs. time curve
for buprenorphine in horses following IV administration
is represented in Figure 3. Buprenorphine was detected
for 8.75 hours in 10/10 horses. Harmonic mean of elim-
ination half-life (T1/2λ) was 6.4 hours (Table 2). Mean
serum concentration of buprenorphine at the last timeFigure 3 Semilogarithmic buprenorphine serum concentrations.
Semilogarithmic buprenorphine serum concentrations (mean ± SD)
over time in ten horses after intravenous injection of 0.0075 mg/kg
buprenorphine.
Table 2 Pharmacokinetic parameters of buprenorphine after 0.0075 mg/kg bwt intravenously in ten horses
Horse λz (h
-1) T1/2λ (h) Vd (L/kg) Cl (mL/min/kg) AUC0-∞ (h·ng/mL) MRT (h)
1 0.12 7.02 3.89 6.40 19.54 6.98
2 0.06 12.09 1.88 1.80 69.39 12.48
3 0.06 8.86 2.90 3.78 33.12 9.25
4 0.12 5.59 0.83 1.71 72.93 5.12
5 0.12 6.79 1.03 1.76 71.17 6.54
6 0.18 3.51 0.56 1.84 67.91 3.47
7 0.06 9.89 3.07 3.59 34.81 11.96
8 0.12 6.85 0.92 1.56 80.33 7.61
9 0.18 4.30 1.69 4.55 27.47 5.09
10 0.12 7.47 3.74 5.78 21.62 9.56
Mean ± SD 0.11 ± 0.04 6.4 ± 2.63* 2.05 ± 1.25 3.28 ± 1.82 49.83 ± 24.37 7.81 ± 2.98
λz, slope of the terminal phase; T1/2λ, half-life of terminal phase; Vd(area), volume of distribution; Cl, Clearance; AUC0-∞, area under the concentration-time curve
extrapolated to infinity; MRT mean residence time. *Harmonic mean ± pseudo SD.
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1.7 ± 0.7 ng/ml.
Discussion
Thermal thresholds determined by ramped contact heat
at the head or the body to assess cutaneous anti-
nociception in horses were comparable. Heat stimulation
at both body sites allowed to recognize a clear end point,
which was repeatable over several hours and responded
to neuroleptic sedation and neuroleptanalgesia in a simi-
lar way.
Type of end point and end point detection in response
to thermal stimulation at different body parts as nostrils
versus withers might influence the TT. With stimulation
at the withers a skin flick was the most clear end point,
whereas stimulation at the nostrils resulted in head
shaking or rubbing the face against an object [14]. In
contrast to the reflex pathway of the skin flick reflex,
which is mediated by the spinothalamic tract [10], re-
sponses to stimulation at the head like head shaking in-
volves the trigeminal nerve and individual conscious
perception and reaction to the stimulus [14]. Head
jerking as part of the nocifensive trigemino cervical
reflex was not observed with heat stimulation in the
current study. Skin twitch at the withers is considered
to be a more clear end point than the hoof withdrawal
reflex, when testing effects of opioids because they inter-
fere with the hoof withdrawal reflex as a result of the in-
crease in spontaneous locomotor activity [5]. Opioids
can also induce head nodding in horses and can make
end point detection at the head more difficult. However,
in the present study there was no difference in skin
temperatures, threshold temperatures and changes in
thresholds between stimulation at the head and the
withers detected. A skin twitch is a very obvious and re-
peatable reaction, however, variability of thermal thresholdsat the nostrils was in fact lower than at the withers,
indicating that the defensive reaction at the head can
repeatedly be detected despite being a more individ-
ual, behavioural response, which is not influenced by
sedation.
Baseline thresholds were stable over 10 consecutive
measurements and no conditioning to the stimulation
procedure or the noxious stimulus was observed in our
study. This is in agreement with previous studies in
horses using a similar stimulation set up [9,14]. In con-
trast, horses became conditioned to the light stimulus
with radiation heat stimulation [3] or to touch with
mechanical pressure stimulation to the front leg before
the stimulus became painful [15].
The standard heating rate of the thermode based sys-
tem for cats (0.85°C/s) resulted in very variable threshold
temperatures and skin lesions in horses [16]. Reducing
the heating rates to 0.5°C/s and 0.2°C/s gave clearer end
points and more consistent threshold temperatures but
also caused restlessness during the lower heating rates
[16]. In contrast, in pretrials with our horse population
the very slow heating rates resulted in burns at the
nostrils. In a previous study stimulation with heating
rates of 0.6°C/s for the withers and 0.8°C/s for the nostril
allowed a clear end point detection without inflamma-
tion or damage of deeper skin layers [14], but might
have contributed to higher TTs compared to other stud-
ies and other species because of a delay in heat transfer
to thermal nociceptors in the face of a rapid increase of
temperature at the skin surface. The necessary differ-
ences in heating rates at the different stimulation sites to
avoid skin damage might be related to differences in skin
architecture and skin thickness resulting in differences
in heat transfer [2]. The chosen heating rates are
thought to activate C-fibre nociceptors and induce low
thermal thresholds like it was shown in rats where slow
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olds activating primarily C-nociceptors [17].
The mode of action of the used drugs is well known in
horses and their sedative and analgesic actions were
used to assess and compare the response of TTs at dif-
ferent body sites. The sedative effect of acepromazine
was variable between horses with a maximum effect
about 45 minutes after injection. The phenothiazine
tranquilizer is widely used in equines [8,18] and is well
known for its dose-dependent sedation [15,18] and lack
of somatic antinociceptive effects [9,15]. Acepromazine
has α1-adrenolytic activity, depresses the vasomotor cen-
ter followed by hypotension, vasodilatation and increased
digital blood flow [19-22]. These effects might interfere
with the regulation of body and skin temperature. Rectal
temperatures weren’t measured in this study, however, a
late decrease in skin temperatures after ACE (Table 1) was
observed at the withers. As contact heat thermal stimula-
tion in the present study was performed during moderate
ambient temperatures (14.8 ± 2.8°C) it can be assumed
that the decrease in skin temperature was probably
influenced by acepromazine.
As expected, buprenorphine, a semi-synthetic partial
mu opioid agonist [23] increased thermal thresholds
measured at the nostril as well as at the withers for sev-
eral hours. In our study thermal thresholds were already
increased above baseline at the first post treatment
stimulation (15 minutes after AB). More frequent stimu-
lation to detect earlier onset was not possible without
active skin cooling. Cut-out was also reached 15 minutes
after administration of butorphanol (0.1 mg/kg, IV) or
buprenorphine (0.005 mg/kg, 0.0075 mg/kg, 0.01 mg/kg,
IV) in a previous study in horses [9].
In the present study anti-nociceptive effects lasted for
approximately 7 hours, which is in close agreement with
a mean duration of anti-nociception of 7.8 hours after
buprenorphine at the same dose reported in a previous
study [9]. Mean serum concentration of buprenorphine
at the last time point with increased TTs (405 minutes
after AB) was 1.7 ± 0.7 ng/mL. Whereas levels of 0.59 ±
0.14 ng/mL (520 minutes after AB) did not result in an-
algesic effects anymore. For a more precise determin-
ation of minimal analgesic serum concentrations the
threshold measurements would need to be performed
more frequently. Therefore the 1.7 ± 0.7 ng/mL can only
be considered a crude estimate for minimal analgesic
serum concentrations of buprenorphine. Elimination
half-life for buprenorphine was 6.4 hours in the current
study, which might even be underestimated as serum
concentrations did not fall below the limit of quantifica-
tion in the terminal phase. However, the determined ter-
minal half-life is comparable to 5.79 hours determined
with a slightly lower dose of buprenorphine (0.006 mg/kg,
IV) [24]. At a buprenorphine dose of 0.005 mg/kgbuprenorphine IV elimination half-life was shorter with
3.58 hours [25] suggesting a dose dependent effect, differ-
ences in sensitivity of the buprenorphine analysis or an in-
fluence of acepromazine co-medication.
Almost all buprenorphine treated horses showed in-
creased locomotor activity and signs of excitation for ap-
proximately 5 hours like it was described in previous
studies [9,24-26]. Locomotor activity became evident
when acepromazine effects declined, which might inter-
fere with the detection of behavioural responses to ther-
mal stimulation [3]. It is discussed controversially whether
opioid induced spontaneous locomotor activity results
from activation of the dopaminergic pathways [27,28]
which might be ameliorated by acepromazine [20]. How-
ever, at the chosen doses the buprenorphine induced
effects outlasted the sedative effects of acepromazine. In a
previous study, sedative effects of acepromazine in horses
were present for 240 minutes after IV injection of
0.15 mg/kg [20] a three times higher dose than in the
current study. The degree of sedation after the acepromzine
and buprenorphine combination was very variable and in
some horses the duration of sedation seemed shorter than
with acepromazine alone, which confirms the observation
that sedative effects with a combination of buprenorphine
and acepromazine in ponies were non-satisfying [29].
Another side effect of buprenorphine combined with
acepromazine was reduction of gastrointestinal sounds
for approximately 5 hours and abdominal discomfort
in one horse 10 hours after drug administration. In
other studies gastrointestinal borborygmi also de-
creased following buprenorphine which was attenuated
when buprenorphine was given sublingually [9,24,26].
When hay was withdrawn 12 hours before intravenous
buprenorphine, there were no signs of abdominal dis-
comfort observed [9].
There was a slight increase in skin temperatures at
both body sites after AB as long as measurements were
performed at 30 minute intervals. Skin temperature in
horses also rose after constant infusion rate with fen-
tanyl [7] but an increase in skin temperature or body
temperature after buprenorphine were not seen in pre-
vious studies [9,24]. It might be possible that the skin
was warming up due to the more frequent heating cy-
cles at the beginning of the observation period in the
current study.
Conclusion
Thermal contact heat stimulation at both described body
sites (nostril and withers) give comparable results in
the assessment of cutaneous nociception in horses.
Buprenorphine combined with acepromazine results in
several hours of cutaneous anti-nociception associated
with locomotor stimulation and reduced gastrointestinal
sounds/activity in healthy horses.
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Animals
The study was approved by the Ethics Committee for
Animal Experiments of Lower Saxony (33.12-42502-04-
10/0136). Eleven warm-blood horses (4 geldings and 7
mares) weighing 600 +/− 95 kg, ranging from 5 to
23 years were used in this randomised, observer-blinded
crossover study. All of them were determined to be
healthy on the basis of results of a physical examination.
Horses were free of acute and chronic lameness. All
horses had the oral cavity and teeth examined and
floated on a regular basis. The mares did not show signs
of behavioural oestrus during the testing periods. During
the study period the horses were housed in a box stall
(4 × 4 m) and had free access to hay and fresh water.
Experimental design
Each horse went through 6 different stimulation condi-
tions including 2 different body sites and 3 different
treatments. All horses in a familiar box stall without re-
straint during constant ambient temperatures (14.8 ±
2.8°C). At least 24 hours before starting the measure-
ments the horses were allowed to get adapted to the en-
vironment (box stall) and the skin at the stimulation
sites was shaved with a razor blade.
Instrumentation
On the day of the experiment an intravenous cathetera
was aseptically placed in a jugular vein following sub-
cutaneous administration of 1.5 ml 2% mepivacaine,b se-
cured with polyamide monofilament nylon suture.c A
wireless thermal threshold testing deviced was attached
to the back of the horse with a belt and Velcro strips.
The thermodes were placed at the withers and lateral to
one nostril and kept at constant contact with the skin by
means of an air bladder pressurized to approximately
80 mmHg (Figure 4).Figure 4 Attachment of the Wireless Thermal Threshold testing
system to the horse. The thermal probes were placed at two
different body parts of the horse (nostril, withers).Experimental protocol
The thermal probes were allowed to equilibrate with
skin temperature and the skin temperature was mea-
sured and recorded. The heating rate was set at 0.6°C/s
for stimulation at the withers and 0.8°C/s for stimulation
at the nostrils [16,30]. The cut-out temperature was set
at 54°C for both locations. The heat controller was set to
start randomly in order to produce a variable delay in
the start of heating so that neither horse nor operator
knew when heating began.
After complete instrumentation, a baseline measure-
ment was performed by heating up the thermal probes
fixed at the nostril and withers. Heating was stopped
and the temperature recorded when the horse shook its
head or rubbed the nose against an object or its legs, a
skin twitch (reflex contraction of the cutaneous trunci
muscle) occurred or the horse turned its head towards
the stimulated site. The type of reaction to the thermal
stimulus was documented. The position of the head, the
ears and the nostril were recorded to assess whether the
horse was nervous or distracted (head held high, ears in
front position and flared nostrils). If the horse didn’t
show a positive behavioural response to thermal stimula-
tion, the cut-out temperature was recorded instead of
the thermal threshold temperature. After each heating
process, the probe was removed from the skin to allow
cooling, and the probe was moved to a new area of skin
for the next measurement.
Overall horses underwent nine thermal stimulations at
each cutaneous site after treatment always in the same
order, first at the nostril, five minutes later at the withers
at regular intervals: 15, 45, 75, 105, 165, 225, 285, 405
and 525 minutes after drug injection.
For determination of the depth of sedation a score for
position of the head as well as reactions to visual and
acoustic stimulation was used (Table 3). Each parameter
was classified from no sedation (0) to deep sedation (3).
Visual stimulation was performed with a red fabric bag
which was suddenly waved in front of the horse’s head.
Acoustic stimulation was done by cracking a plastic bag
behind the examiners back to avoid concurrent visual
stimulation. Gastrointestinal sounds were recorded as
normal, decreased or absent following auscultation in all
4 quadrants [25] and excitatory phenomena (restless-
ness, head shaking, increased tear production or saliva-
tion) were documented. When the experiment was
finished, the skin was checked for lesions or swelling
caused by the heating probe.
Treatments
Horses were randomly assigned to receive 1 out of 3
treatments, with a washout period of at least 14 days: sa-
line solutione IV (S); acepromazinef 0.05 mg/kg IV
(ACE); buprenorphineg 0.0075 mg/kg combined with
Table 3 Sedation score
Head position 0 lower lip at height of shoulder joint or higher
1 lower lip between shoulder and olecranon
2 lower lip between olecranon and carpal joint
3 lower lip at carpal joint or lower
Reaction to acoustic stimulation 0 moving back, normal reaction
1 mildly curbed reaction
2 clearly curbed reaction
3 no reaction
Reaction to visual stimulation 0 moving back, normal reaction
1 mildly curbed reaction
2 clearly curbed reaction
3 no reaction
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was made equal to 20 mL among different treatments
and the drug was administered via a jugular catheter
over 1 minute by a person not involved in the trial.
When measurements were completed, the intravenous
catheter was removed and iodine ointmenth placed over
the puncture site.
Sample collection and drug analysis
Blood samples were collected prior to drug administra-
tion, directly after baseline measurement of thermal
stimulation (baseline), as well as after each thermal
stimulation at 15, 45, 75, 105, 165, 225, 285, 405 and
525 minutes after drug administration. Ten ml of blood
were collected from the jugular catheter into a syringe
and discarded; then samples were collected (9 ml) and
placed in test tubesi with serum clot activator and were
centrifuged two hours later with 3600 rotations/min
(~2800 G) for 6 minutes. Then serum was transferred
with disposable pipettes into three 1-ml cryogenic plastic
storage tubesj and stored at −80°C until analysis. The
jugular catheter was flushed with 10 ml heparinzed sa-
line solution before and after each blood sampling.
Serum samples of ten horses (samples from one horse
got lost) were analysed with high-performance liquid
chromatography with a tandem mass spectrometer
(HPLC MSMS)k in the commercial laboratory.l Serum
samples were thawed at room temperature. According
to laboratory standard 5 ng Buprenorphine-D4 and
100 μl saturated Borax solution were added to the sam-
ples adjust to pH = 9.2. The mixture was extracted with
1 ml Ethyl acetate. After centrifugation the organic layer
was separated and evaporated to dryness under nitrogen.The residue was dissolved with 100 μl acetonitrile and
measured using an Agilent 1200SL HPLC system coupled
to an Agilent 6460 mass spectrometer with an electro-
spray ion source operated in positive mode. An Agilent
Zorbax SB-C18 150 × 2.1 mm, 3.5 μm was used as station-
ary phase. Mobile phase was acetonitrile (A) and 0.1%
formic acid in water (B). Gradient started at 95% B to 30%
B within 7.5 min. Injection volume was 5 μl. Parameters
of the Jet stream source: Drying gas Temp/Flow: 250°C/
10 l min-1, Sheath gas 400/10, Capillary voltage 4500 V,
Nozzel voltage 0 V. Calibration curves for buprenorphine
were prepared by using buprenorphine spiked serum.
Limit of quantitation was 0.05 ng/ml. The calibration
curve was linear within 0.1 and 5 ng/mL. Intra-assay
precision at buprenorphine concentrations of 10 ng/mL
was 8.4%.
A protein precipitation technique using acetate was
performed, followed by a solid phase extraction. The mo-
lecular mass of 427 Dalton corresponded to buprenorphine.
Calibration curves for buprenorphine were prepared by
using equine serum spiked with known buprenorphine
concentrations. Limits of quantitation were determined to
be 0.05 ng/mL. Intra-assay precision at buprenorphine con-
centrations of 10 ng/mL was 8.4%.
Pharmacokinetic analysis
Serum concentrations of buprenorphine were analysed
using commercial software.m Noncompartmental ana-
lysis was used to derive the slope of the terminal phase
(λz), half-life of the terminal phase (T1/2λ), area under
the concentration-time curve extrapolated to infinity
(AUC0-∞) determined be the trapezoid method, apparent
volume of distribution (Vd area), and mean residence
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pharmacokinetic calculations [31].
Statistical and data analysis
Normal distribution of data was approved by visual as-
sessment of the q-q-plots of the model residuals. Data
were reported as mean ± standard deviation.
For standardizing thermal thresholds the following equa-
tion was used for calculating percent of thermal excursion:
TE % = 100 × ([TT ‐T0]/[Tc ‐ T0]). TT is the thermal
threshold temperature, T0 is the skin temperature and
Tc is the thermal cut-out temperature [32].
Influence of drug administration and body site of the
horse were analysed using a two-way analysis of variance
(ANOVA) with repeated measurements within subjects
and post-hoc Tukey-Kramer test for multiple pair wise
comparisons. Statistical significance was attributed when
p < 0.05. Analyses were carried out with commercial
statistical softwaren and graphs were prepared with
graphical software.o
Endnotes
a 12 SWG, EquiCathTM Fastflow, Braun Vet Care GmbH,
Tuttlingen, Germany.
b Scandicain®, AstraZeneca GmbH, Wedel, Germany.
c Dafilon® 1 metric, B. Braun, Aesculap AG, Tuttlingen,
Germany.
d Topcat Metrology Ltd., Little Downham, Ely, UK.
e 0.9% natriumchlorid solution, B. Braun Melsungen
AG, Melsungen, Germany.
f Vetranquil® 1%, Albrecht GmbH, Aulendorf, Germany.
g Temgesic®, Essex Pharma GmbH, München, Germany.
h Vet-Sept®, Albrecht GmbH, Aulendorf, Germany.
i Vacuette®, Greiner Bio-One GmbH, Kremsmünster,
Austria.
j Eppendorf cuvettes, Eppendorf- Netheler- Hinz GmbH,
Hamburg, Germany.
k Agilent 6400 Sereis, Triple Quad LC/MS system, Santa
Clara, CA.
l LIPIDOMIX GmbH, Dr. rer. nat. M. Rothe, Berlin,
Germany.
m PK Solutions 2.0 TM, Summit Research Services,
Pharmacokinetics and Metabolism Software, Montrose,
USA.
n SAS® version 9.2, SAS Institute, NC, USA.
o GraphPad Prism® version 5.03, GraphPad Software, Inc.,
CA, USA.
Additional file
Additional file 1: Side effect after AB administration. The first horse
seen in the video showed unconscious head nodding two minutes after
AB administration for 3 minutes. One horse was deeply sedated (score: 8).
Further horses were restless and showed box walking 3 – 4 hours after
AB administration.Abbreviations
AB: Acepromazine and buprenorphine; ACE: Acepromazine; N: Nostril;
S: Saline solution; TE %: Percentage of thermal excursion; TT: Thermal
thresholds in °C; W: Withers; WTT2: Wireless thermal threshold testing device
2 (modified for horses).
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